Company Summary

Investment Profile

1. Innovative exosome drug delivery platform underpinned by robust IP
2. Income generating cell line development and licensing business
3. Strong diversified revenue strategy
4. Growing advanced therapeutics market

Company Overview

ReNeuron Group plc is a biotechnology company harnessing the natural biology of exosomes to develop next-generation drug delivery system. The Company was founded in 1997 and has been at the forefront of cell-based technologies for over two decades.

Experienced Management Team

- Total of >50years board and executive experience in life sciences
- Multiple new platforms and medicines overseen to development and commercialisation
- >$1b of capital raised for public & private companies
- International networks in finance, research, drug development and professional services

Iain Ross, BSc CDir
Chairman

Dr Randolph Corteling, PhD
Managing Director & CSO

Dr Barbara Staehelin, MSc MBA
Non-Executive Director

CustomEX™

ReNeuron's **CustomEX is a customisable, exosome-based, targeted drug delivery platform** for modern therapeutics which exploits the natural function of stem cell-derived exosomes to target and deliver payloads to specific cells and tissues. The platform has the **potential to overcome many of the current limitations of traditional delivery platforms**, such as penetration across biological barriers, immunogenicity, and lack of cellular targeting.

Unlike other approaches in the field, the CustomEX platform sets itself apart by using a catalogue of proprietary stem-cell lines, each designed to produce exosomes with unique, cell-type-specific properties. These exosomes naturally target specific tissues, enabling highly selective and efficient drug delivery. By offering access to a diverse range of producer cell types, CustomEX allows for precise matching of exosome characteristics to therapeutic needs—unlocking new possibilities for targeted treatments and accelerating development timelines. This modular approach positions CustomEX as a potentially powerful addition to next-generation drug delivery solutions.



Overcoming barriers to drug delivery

Delivery is a major hurdle that continues to hold back the clinical development of many complex drug modalities. In particular, the effective and safe targeting of extrahepatic tissues remains a significant obstacle for the development and translation of advanced therapeutics from the lab to the clinic. Despite huge advances in the field, there are a staggering number of diseases that do not have a developed treatment, which is partly due to there being a lack of appropriate tissue targeting delivery vehicles. These diseases continue to burden healthcare systems and contribute to global deaths rates. The advanced therapeutics market is growing significantly, but market size is limited by lack of targeted delivery beyond the liver. ReNeuron's CustomEX platform presents a strong solution and opportunity in the targeted delivery of advanced therapeutic modalities, featuring proprietary loading technology for a variety of therapeutic cargos, including small molecular weight drugs, proteins, and nucleic acids.

For more information email: reneuron@walbrookpr.com
Tel: 020 7933 8780; web: www.walbrookpr.com

The ReNeuron advantage

ReNeuron's CustomEX platform is built on conditional immortalisation technology—validated in our clinical programmes—to create genetically engineered, highly stable exosome producer cell lines. This enables a consistent and scalable manufacturing process, delivering exosomes at a commercially relevant scale. ReNeuron has been at the forefront of this technology for over 20 years and the Company's cell lines have **10+ years of clinical safety data** for the immortalisation technology.

CustomEX exosomes are confirmed to cross biological barriers and target specific cells unlike viral vectors and LNPs. There is also no sign of immune response or toxicity, resulting in the possible use of CustomEX for repeat administration. ReNeuron has established an **innovative exosome delivery platform underpinned by robust IP** which has already demonstrated organ specific tropism and differentiation from other exosome technologies.

Precision disease modelling

Another key challenge in drug discovery has been a historical lack of good model cell lines for primary screening. Many cell models are based on cancer cell lines, which have numerous genetic changes compared to the cell type of interest and are normally not representative of the disease of interest.

ReNeuron's technology is not only unique and protected by an extensive know-how and trade secrets, but also provides a **significant advantage over traditional models**, such as iPSC methods. This includes the ease of culture, stability, replicative capacity and availability of patient and genotype matched cell types. These advantages collectively offer new opportunities for cell-based models in the following applications and allow ReNeuron's established lines to be used for the development of precision disease modelling:

- Target engagement/validation
- High throughput screening of advanced therapies
- Identification of off target effects
- Novel target discovery
- Predict interactions and off target effects
- Predict safety and toxicological testing
- Lead optimisation and efficacy evaluation
- Development of 2D and 3D cell models – co-culture with patient matched cells

Proven track record in scientific studies

>400 publications using ReNeuron's ReNcell platform (ReNcell VM and CX, marketed through Millipore)

>50 publications using ReNeuron's conditionally immortalised (CI) cell lines

**Number of publications as of April 2025*

How can ReNeuron make a difference?

ReNeuron has developed **20+ human stem cell lines** from a variety of tissues, using the same immortalisation technology developed for the Company's clinical programmes, providing a **unique and diversified portfolio of stem cell types available to license**. Cell lines which can be utilised immediately for R&D purposes include:

- CNS focused – Cortical, Hippocampal, Striatal, Spinal Cord, Ventral Mesencephalon, Cerebellum
- Other cell types – Liver, Pancreatic, Retinal

Indications include Alzheimer's, Parkinson's, Stroke/TBI, Spinal cord injury, Retinal disease, Diabetes and metabolic disease, as well as many other diseases.



ReNeuron's Mission

The Company's mission, through its CustomEX platform, remains in **overcoming barriers to drug delivery and drive innovation within the industry**. CustomEX will enable the targeted delivery of advanced therapeutic modalities, such as siRNA, mRNA and gene editing complexes, with the **potential to develop the next generation of gene therapies for previously untreatable diseases** of the central nervous system, lungs and kidney. This will be facilitated by the licensing of the Company's distinct cell lines, allowing for the realisation of a **cost-effective R&D business model and new revenue streams** within the business.